anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

204,961-205,020 of 319,975

filter-aware
43
Includes a footnote regarding the definition of Adjusted EBITDA and rounding differences.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
44
Cano Health | Investor Presentation Deck | 48 slidesCano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
45
Includes detailed footnotes explaining the non-GAAP adjustments and the definition of the metrics used.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
46
The chart highlights a significant reduction in hospital utilization, a key performance metric for value-based care providers.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
47
The chart shows a significant compression in valuation multiples across the peer group over the two-year period.Cano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
48
Cano Health | Investor Presentation Deck | 48 slidesCano Health | Investor Presentation Deck | 48 slides · Cano Health
Pitch deck Investor relations 1 hit
01
Slide 1
Cano Health | Results Presentation Deck | 19 slidesCano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations 1 hit
02
Cano Health | Results Presentation Deck | 19 slidesCano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations 1 hit
03
Cano Health | Results Presentation Deck | 19 slidesCano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations 1 hit
04
The slide uses a visual equation (Icon + Icon + Icon) to summarize the business model.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations 1 hit
05
Uses a standard 5-column pillar layout to summarize the company's value proposition.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a 3x2 grid layout to present key performance indicators and forward-looking guidance.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
07
Uses a diamond-shaped diagram to represent the core pillars of the care model and growth strategy.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide highlights a strategic shift toward consolidation in 1Q23, particularly in Florida.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Market SizeLoop · Pareto Focus1 hit
09
The chart shows a J-curve effect for de novo medical center profitability.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
10
Includes non-GAAP financial measure disclaimers.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · FinancialsLoop · Pareto Focus1 hit
11
Cano Health | Results Presentation Deck | 19 slidesCano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
12
Includes a disclaimer note about rounding differences.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
13
The slide contains two distinct data tables: one for raw member counts and one for percentage distribution.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
14
Includes a disclaimer about rounding differences.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
15
Includes a footnote regarding the definition of Adjusted EBITDA and rounding.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
16
Includes footnotes defining Medical Cost Ratio and Adjusted EBITDA, and a note on rounding.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
17
The slide includes a detailed reconciliation table and a legend for specific adjustments (A-F).Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
18
The chart shows a downward trend in hospital admissions over the period.Cano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations Beat · Financials1 hit
19
Cano Health | Results Presentation Deck | 19 slidesCano Health | Results Presentation Deck | 19 slides · Cano Health
Conference presentation Investor relations 1 hit
01
Slide 1
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
02
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
03
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style chart to map drug candidates against development phases.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
05
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
06
Includes Kaplan-Meier survival curves and a comparative table of clinical outcomes.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · Problem StatementLoop · Cost Of Inaction1 hit
07
Data presented includes ORR, DOR, time to response, disease control rate, PFS, and overall survival metrics.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
08
The slide details specific inclusion/exclusion criteria including age, mutation status, disease progression, prior therapy, and washout periods.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
09
The slide highlights clinical response rates (20-26%) and disease control rates (40-42%) using rigorous BICR methodology.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
10
The chart is a waterfall plot (often called a swimmer plot or spider plot in oncology, but specifically a waterfall plot here).Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide uses a waterfall plot to visualize tumor shrinkage (Best % Change in SPD) across different patient performance status cohorts.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
The chart is a 'spider plot' or 'swimmer plot' variant showing % change in tumor size over time.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
13
Presents safety data tables for two distinct patient populations.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
14
Data table comparing All patients vs RANO HGG Responders vs RANO HGG and/or LGG Responders across survival and clinical metrics.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
15
The table uses a color-coded heatmap (green/pink) to indicate positive vs negative characteristics of trial design and outcomes.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
16
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
17
The slide uses a process flow diagram to illustrate the clinical trial structure.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
18
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
19
The slide details specific statistical success thresholds for different trial endpoints.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
20
The chart shows a dose-response curve where longer incubation times (48+ hours) shift the curve to the left compared to 24 hours, indicating higher potency/efficacy with sustained exposure.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · Solution1 hit
21
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
22
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Beat · Market Sizing1 hit
23
The slide lists specific regulatory milestones achieved for glioma treatments.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
24
Clinical trial data (NCT03034200) presented at ASCO 2021.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
25
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
26
Includes a BioRender diagram illustrating the molecular pathway.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
27
Includes PET scan imagery and comparative bar/dot plots.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
28
Includes a schematic of the mutation, a bar chart of H3K27me3 levels, a Kaplan-Meier survival curve, and a dot plot showing treatment effect.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
29
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
30
Includes molecular structure of ONC206 and protein structures for DRD2 and ClpP.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
31
The slide uses a human body diagram to categorize tumor types and presents preclinical data for each.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
32
The slide uses two charts: a dose-response curve showing increased efficacy with longer incubation times, and a PK model showing plasma concentration over time relative to a therapeutic window.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
33
The slide highlights early clinical efficacy data from a dose escalation trial.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
34
Includes a visual representation of survival rates (1 out of 20).Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
35
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit